Sharma Mousumi, Sharma Jagannath Dev, Sarma Anupam, Ahmed Shiraj, Kataki Amal Chandra, Saxena Rahul, Sharma Dilutpal
Pathology, Dr. B. Borooah Cancer Institute, Guwahati, India E-mail:
Asian Pac J Cancer Prev. 2014;15(11):4507-11. doi: 10.7314/apjcp.2014.15.11.4507.
Breast cancer is a heterogeneous disease comprising of distinct biological subtypes with many targeted prognostic biomarkers having therapeutic implications. However, no specific targeted therapy for triple negative breast cancer has been discovered to date and hence further research is needed.
The aim and objectives of the present study were to examine the prevalence of triple negative breast cancer (TNBC) in North-East India and to compare the clinicopathological parameters in two study groups defined by immunohistochemistry (IHC) -"TNBC" and "Others".
We carried out a retrospective study in a cohort of 972 patients diagnosed with invasive breast carcinoma in the Department of Pathology, Dr. B. Borooah Cancer Institute, a Regional Cancer Centre for treatment and research, Guwahati, for a period of 3 years and 10 months from January 2010 to October 2013. Based on IHC findings, patients were divided into two groups - "TNBC" and "Others". All relevant clinicopathological parameters were compared in both. TNBC were defined as those that were estrogen receptor (ER), progesterone receptor (PR), and HER2/neu negative while those positive for any of these markers were defined as "Others".
In this study, out of total 972 cases 31.9% (310 cases) were defined as TNBC and 662 cases (68.1%) as "Others" based on IHC markers. Compared to the "Others" category, TNBC presented at an early age (mean 40 years), were associated with high grade large tumours and high rate of node positivity, IDC NOS being the most common histological subtype in TNBC.
TNBC accounts for a significant portion of breast cancers in this part of India and commonly present at younger age and tend to be large high grade tumours.
乳腺癌是一种异质性疾病，由不同的生物学亚型组成，有许多靶向预后生物标志物具有治疗意义。然而，迄今为止尚未发现针对三阴性乳腺癌的特异性靶向治疗方法，因此需要进一步研究。
本研究的目的是调查印度东北部三阴性乳腺癌（TNBC）的患病率，并比较通过免疫组织化学（IHC）定义的两个研究组——“TNBC”和“其他组”的临床病理参数。
我们在一家区域癌症治疗与研究中心——古瓦哈蒂的B. 博罗阿癌症研究所病理科，对972例诊断为浸润性乳腺癌的患者进行了一项回顾性研究，研究时间为2010年1月至2013年10月，为期3年零10个月。根据免疫组化结果，将患者分为两组——“TNBC”和“其他组”。比较两组所有相关的临床病理参数。TNBC定义为雌激素受体（ER）、孕激素受体（PR）和HER2/neu均为阴性的患者，而这些标志物中任何一项呈阳性的患者定义为“其他组”。
在本研究中，根据免疫组化标志物，972例病例中31.9%（310例）被定义为TNBC，662例（68.1%）为“其他组”。与“其他组”相比，TNBC发病年龄较早（平均40岁），与高级别大肿瘤和高淋巴结阳性率相关，浸润性导管癌非特殊型（IDC NOS）是TNBC中最常见的组织学亚型。
TNBC在印度这一地区的乳腺癌中占很大比例，通常发病年龄较轻，且往往是高级别大肿瘤。
